The trial is designed to evaluate the contribution of the ICS component on lung function, in patients with Chronic Obstructive Pulmonary Disease (COPD). According to GSK, positive results
Orphan drug status provides incentives to the BioThrax PEP Program, including the waiver of the Biologics License Application (BLA) supplemental regulatory filing fee and marketing exclusivity of up
As part of the option agreement, Amunix will receive an upfront $1m payment and will also be eligible to receive up to $38m in clinical and commercial milestone
For the 12 months ending February 2014, the US market for Adenosine Injection, USP approximated $28m, according to IMS. As with all products in the company’s portfolio, Adenosine
As part of the deal, Novartis would have opt-in rights to GSK’s current and future oncology R&D pipeline. The deal will see Novartis divest its Vaccines business (excluding
The company said that in this case, the patent will be for the treatment of patients suffering a stroke. Researchers at the Henry Ford Hospital in Detroit, US,
The company is developing ceftolozane/tazobactam for the treatment of certain Gram-negative infections. The NDA is based on positive data from pivotal Phase III clinical trials in cUTI and
The approval makes CYRAMZA, the first FDA-approved treatment for patients with metastatic gastric cancer. Lilly Oncology senior vice president of product development and medical affairs Richard Gaynor said
Pursuant to the terms of the research collaboration agreement, NanoSmart Pharmaceuticals and NanoValent Pharmaceuticals will explore the feasibility of jointly developing an anti-nuclear antibody (ANA)-conjugated liposomal doxorubicin nanoparticle
Volasertib is an investigational compound that inhibits enzymes called Polo-like kinase. Currently, the drug is being assessed in a Phase III clinical trial for the treatment of patients
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.